Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated:  12/31/1969
Urology Associates
943
mi
from 02139
Nashville, TN
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated: 12/31/1969
Urology Associates
943
mi
from 02139
Nashville, TN
Click here to add this to my saved trials
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
940
mi
from 02139
Nashville, TN
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
940
mi
from 02139
Nashville, TN
Click here to add this to my saved trials
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated:  12/31/1969
Urology Clinics of North Texas
1540
mi
from 02139
Dallas, TX
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated: 12/31/1969
Urology Clinics of North Texas
1540
mi
from 02139
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated:  12/31/1969
Texas Oncology-Baylor Charles A. Sammons Cancer Center
1545
mi
from 02139
Dallas, TX
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated: 12/31/1969
Texas Oncology-Baylor Charles A. Sammons Cancer Center
1545
mi
from 02139
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Memorial City
1608
mi
from 02139
Houston, TX
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Memorial City
1608
mi
from 02139
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated:  12/31/1969
Urology San Antonio Research
1763
mi
from 02139
San Antonio, TX
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated: 12/31/1969
Urology San Antonio Research
1763
mi
from 02139
San Antonio, TX
Click here to add this to my saved trials
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated:  12/31/1969
University of Utah (Huntsman Cancer Hospital)
2088
mi
from 02139
Salt Lake City, UT
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated: 12/31/1969
University of Utah (Huntsman Cancer Hospital)
2088
mi
from 02139
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated:  12/31/1969
University of Utah, Huntsman Cancer Institute
2088
mi
from 02139
Salt Lake City, UT
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated: 12/31/1969
University of Utah, Huntsman Cancer Institute
2088
mi
from 02139
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated:  12/31/1969
Virginia Oncology Associates
462
mi
from 02139
Hampton, VA
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated: 12/31/1969
Virginia Oncology Associates
462
mi
from 02139
Hampton, VA
Click here to add this to my saved trials
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated:  12/31/1969
Virginia Oncology Associates
467
mi
from 02139
Norfolk, VA
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated: 12/31/1969
Virginia Oncology Associates
467
mi
from 02139
Norfolk, VA
Click here to add this to my saved trials
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated:  12/31/1969
Urology of Virginia, PLLC
468
mi
from 02139
Virginia Beach, VA
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated: 12/31/1969
Urology of Virginia, PLLC
468
mi
from 02139
Virginia Beach, VA
Click here to add this to my saved trials
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated:  12/31/1969
Virginia Mason Medical Center
2483
mi
from 02139
Seattle, WA
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated: 12/31/1969
Virginia Mason Medical Center
2483
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated:  12/31/1969
Seattle Cancer Care Alliance
2482
mi
from 02139
Seattle, WA
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated: 12/31/1969
Seattle Cancer Care Alliance
2482
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated:  12/31/1969
University of Washington Medical Center
2481
mi
from 02139
Seattle, WA
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated: 12/31/1969
University of Washington Medical Center
2481
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Clinical Sciences Center
929
mi
from 02139
Madison, WI
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Clinical Sciences Center
929
mi
from 02139
Madison, WI
Click here to add this to my saved trials
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated:  12/31/1969
George Washington University Medical Faculty Associates
392
mi
from 02139
Washington,
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated: 12/31/1969
George Washington University Medical Faculty Associates
392
mi
from 02139
Washington,
Click here to add this to my saved trials
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated:  12/31/1969
Standford Health Care
2687
mi
from 02139
Stanford, CA
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated: 12/31/1969
Standford Health Care
2687
mi
from 02139
Stanford, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated:  12/31/1969
Anschutz Inpatient Pavilion
1755
mi
from 02139
Aurora, CO
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY
Status: Enrolling
Updated: 12/31/1969
Anschutz Inpatient Pavilion
1755
mi
from 02139
Aurora, CO
Click here to add this to my saved trials
Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking
Randomized Placebo-Controlled Phase 2 Pilot Study of Memantine (Namenda) for Smoking Cessation Among Cancer Survivors
Status: Enrolling
Updated:  12/31/1969
Wake Forest Cancer Center CCOP Research Base
mi
from 02139
Winston-Salem, NC
Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking
Randomized Placebo-Controlled Phase 2 Pilot Study of Memantine (Namenda) for Smoking Cessation Among Cancer Survivors
Status: Enrolling
Updated: 12/31/1969
Wake Forest Cancer Center CCOP Research Base
mi
from 02139
Winston-Salem, NC
Click here to add this to my saved trials
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated:  12/31/1969
Prostate Oncology Specialists, Inc.
2601
mi
from 02139
Marina Del Rey, CA
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated: 12/31/1969
Prostate Oncology Specialists, Inc.
2601
mi
from 02139
Marina Del Rey, CA
Click here to add this to my saved trials
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated:  12/31/1969
IU Health Bloomington Hospital
835
mi
from 02139
Bloomington, IN
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated: 12/31/1969
IU Health Bloomington Hospital
835
mi
from 02139
Bloomington, IN
Click here to add this to my saved trials
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated:  12/31/1969
IU Health Goshen Hospital
757
mi
from 02139
Goshen, IN
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated: 12/31/1969
IU Health Goshen Hospital
757
mi
from 02139
Goshen, IN
Click here to add this to my saved trials
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated:  12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
802
mi
from 02139
Indianapolis, IN
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated: 12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
802
mi
from 02139
Indianapolis, IN
Click here to add this to my saved trials
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated:  12/31/1969
IU Health Central Indiana Cancer Centers
802
mi
from 02139
Indianapolis, IN
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated: 12/31/1969
IU Health Central Indiana Cancer Centers
802
mi
from 02139
Indianapolis, IN
Click here to add this to my saved trials
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated:  12/31/1969
Northern Indiana Cancer Research Consortium
777
mi
from 02139
South Bend, IN
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated: 12/31/1969
Northern Indiana Cancer Research Consortium
777
mi
from 02139
South Bend, IN
Click here to add this to my saved trials
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
2
mi
from 02139
Boston, MA
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
2
mi
from 02139
Boston, MA
Click here to add this to my saved trials
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated:  12/31/1969
University of New Mexico Cancer Center: Albuquerque
1963
mi
from 02139
Albuquerque, NM
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated: 12/31/1969
University of New Mexico Cancer Center: Albuquerque
1963
mi
from 02139
Albuquerque, NM
Click here to add this to my saved trials
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated:  12/31/1969
Virginia Oncology Associates
467
mi
from 02139
Norfolk, VA
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated: 12/31/1969
Virginia Oncology Associates
467
mi
from 02139
Norfolk, VA
Click here to add this to my saved trials
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
1079
mi
from 02139
Rochester, MN
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
1079
mi
from 02139
Rochester, MN
Click here to add this to my saved trials
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated:  12/31/1969
Alberta Health Services: Tom Baker Cancer Centre
2089
mi
from 02139
Calgary,
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status: Enrolling
Updated: 12/31/1969
Alberta Health Services: Tom Baker Cancer Centre
2089
mi
from 02139
Calgary,
Click here to add this to my saved trials
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
A Phase I and Randomized Phase II Multicenter Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
A Phase I and Randomized Phase II Multicenter Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
Click here to add this to my saved trials
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
A Phase 2 Study Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Northwestern University
847
mi
from 02139
Evanston, IL
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
A Phase 2 Study Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Northwestern University
847
mi
from 02139
Evanston, IL
Click here to add this to my saved trials
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
A Phase 2 Study Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
2530
mi
from 02139
Portland, OR
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
A Phase 2 Study Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
2530
mi
from 02139
Portland, OR
Click here to add this to my saved trials
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
A Phase 2 Study Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
184
mi
from 02139
New York, NY
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
A Phase 2 Study Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
184
mi
from 02139
New York, NY
Click here to add this to my saved trials
Cabozantinib for Advanced Urothelial Cancer
A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
Cabozantinib for Advanced Urothelial Cancer
A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
Click here to add this to my saved trials
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
A Randomized, Double-Blind Phase II Study of Sipuleucel-T (Provenge®) Followed by Indoximod or Placebo in the Treatment of Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
University of Illinois Medical Center
849
mi
from 02139
Chicago, IL
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
A Randomized, Double-Blind Phase II Study of Sipuleucel-T (Provenge®) Followed by Indoximod or Placebo in the Treatment of Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
University of Illinois Medical Center
849
mi
from 02139
Chicago, IL
Click here to add this to my saved trials
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
A Randomized, Double-Blind Phase II Study of Sipuleucel-T (Provenge®) Followed by Indoximod or Placebo in the Treatment of Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Masonic Cancer Center at University of Minnesota
1117
mi
from 02139
Minneapolis, MN
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
A Randomized, Double-Blind Phase II Study of Sipuleucel-T (Provenge®) Followed by Indoximod or Placebo in the Treatment of Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Masonic Cancer Center at University of Minnesota
1117
mi
from 02139
Minneapolis, MN
Click here to add this to my saved trials
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
A Randomized, Double-Blind Phase II Study of Sipuleucel-T (Provenge®) Followed by Indoximod or Placebo in the Treatment of Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
New York Presbyterian-Weill Cornell Medical Center
184
mi
from 02139
New York, NY
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
A Randomized, Double-Blind Phase II Study of Sipuleucel-T (Provenge®) Followed by Indoximod or Placebo in the Treatment of Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
New York Presbyterian-Weill Cornell Medical Center
184
mi
from 02139
New York, NY
Click here to add this to my saved trials
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
A Randomized, Double-Blind Phase II Study of Sipuleucel-T (Provenge®) Followed by Indoximod or Placebo in the Treatment of Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Penn State Milton S. Hershey Medical Center
321
mi
from 02139
Hershey, PA
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
A Randomized, Double-Blind Phase II Study of Sipuleucel-T (Provenge®) Followed by Indoximod or Placebo in the Treatment of Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
321
mi
from 02139
Hershey, PA
Click here to add this to my saved trials
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(2)
1763
mi
from 02139
San Antonio, TX
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(2)
1763
mi
from 02139
San Antonio, TX
Click here to add this to my saved trials
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Univ Wisc
927
mi
from 02139
Madison, WI
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Univ Wisc
927
mi
from 02139
Madison, WI
Click here to add this to my saved trials
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Seattle Cancer Care Alliance Dept. of SCCA
2483
mi
from 02139
Seattle, WA
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Seattle Cancer Care Alliance Dept. of SCCA
2483
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from 02139
Bouge,
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from 02139
Bouge,
Click here to add this to my saved trials
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
UCSF Medical Center Dept of Oncology
mi
from 02139
San Francisco, CA
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
UCSF Medical Center Dept of Oncology
mi
from 02139
San Francisco, CA
Click here to add this to my saved trials
Does Protein Restriction Inhibit Prostrate Cancer Growth
Does Protein Restriction Inhibit Prostrate Cancer Growth
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
1036
mi
from 02139
Saint Louis, MO
Does Protein Restriction Inhibit Prostrate Cancer Growth
Does Protein Restriction Inhibit Prostrate Cancer Growth
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
1036
mi
from 02139
Saint Louis, MO
Click here to add this to my saved trials
Neoadjuvant BKM120 in High-risk Prostate Cancer
A Pharmacodynamic Study of Pre-prostatectomy BKM120 in Men With High-risk, Localized Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
2692
mi
from 02139
San Francisco, CA
Neoadjuvant BKM120 in High-risk Prostate Cancer
A Pharmacodynamic Study of Pre-prostatectomy BKM120 in Men With High-risk, Localized Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
2692
mi
from 02139
San Francisco, CA
Click here to add this to my saved trials
Cabozantinib in Men With Castration-Resistant Prostate Cancer
A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and the Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Seattle Cancer Care Alliance / University of Washington
2483
mi
from 02139
Seattle, WA
Cabozantinib in Men With Castration-Resistant Prostate Cancer
A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and the Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Seattle Cancer Care Alliance / University of Washington
2483
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer
Pilot Trial of Sipuleucel-T, With or Without pTVG-HP DNA Booster Vaccine, in Patients With Castrate-Resistant, Metastatic Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Carbone Cancer Center
929
mi
from 02139
Madison, WI
Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer
Pilot Trial of Sipuleucel-T, With or Without pTVG-HP DNA Booster Vaccine, in Patients With Castrate-Resistant, Metastatic Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Carbone Cancer Center
929
mi
from 02139
Madison, WI
Click here to add this to my saved trials
Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
A Phase II Trial of Abiraterone Acetate, Radiotherapy and Short-Term Androgen Deprivation in Men With Unfavorable Risk Localized Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Durham Regional Hospital
602
mi
from 02139
Durham, NC
Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
A Phase II Trial of Abiraterone Acetate, Radiotherapy and Short-Term Androgen Deprivation in Men With Unfavorable Risk Localized Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Durham Regional Hospital
602
mi
from 02139
Durham, NC
Click here to add this to my saved trials
Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
A Phase II Trial of Abiraterone Acetate, Radiotherapy and Short-Term Androgen Deprivation in Men With Unfavorable Risk Localized Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
601
mi
from 02139
Durham, NC
Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
A Phase II Trial of Abiraterone Acetate, Radiotherapy and Short-Term Androgen Deprivation in Men With Unfavorable Risk Localized Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
601
mi
from 02139
Durham, NC
Click here to add this to my saved trials